FDA Adverse Event Injury Summary report: N

PROTIME 3 CUVETTE ASSAY

MDR report key: 2994354 · Received March 5, 2013

Report

Report Number
2248721-2013-00012
Event Type
Injury
Date Received
March 5, 2013
Date of Event
January 1, 2013
Report Date
February 5, 2013
Manufacturer
INTERNATIONAL TECHNIDYNE CORPORATION
Product Code
GJS
PMA / PMN Number
K010599
Removal / Correction Number
2248721-09/19/12-001
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
MI, US
Reporter Occupation
NOT APPLICABLE

Narratives

Additional Manufacturer Narrative · 1

THIS MDR SUBMITTED ON (B)(4) 2013 REFERENCE ITC COMPLAINT (B)(4). MFR NOTIFIED FDA ON (B)(4) 2012 OF PROTIME 3 CUVETTES VOLUNTARY RECALL. PROTIME 3 CUVETTES WITHIN A SPECIFIED LOT RANGE MAY RECOVER LOWER THAN EXPECTED PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT/INR) RESULTS. ITC'S INVESTIGATION INTO THE PRODUCT'S PERFORMANCE IDENTIFIED MFG PROCESS, QC, AND PRODUCT SURVEILLANCE PARAMETERS AS CONTRIBUTORY TO THE UNDER RECOVERY AND INCONSISTENT RESULTS ARE NOW BEING CONTROLLED SUCH THAT ALL FUTURE PRODUCT MEETS ALL SPEC WITH MINIMIZED VARIABILITY AND BIAS TO ENSURE CLINICAL EQUIVALENCY TO INR REFERENCE STANDARDS. ITC HAS REQUESTED ALL DATA REQUIRED FOR FORM 3500A.

Description of Event or Problem · 1

PT SELF-TESTER REPORTS LOWER THAN EXPECTED RESULTS WITH THE PROTIME MICROCOAGULATION SYSTEM. PT REPORTED TESTING WITH A RECALLED LOT OF PROTIME3 CUVETTES AND WAS GENERATING RESULTS OF APPROX 1.7 INR. UPON INCREASING HER COUMADIN DOSE, INR REMAINED LOWER THAN EXPECTED. PT WENT TO THE EMERGENCY ROOM TO HAVE A LAB TEST PERFORMED AND SHE WAS EXPERIENCING A BAD HEADACHE, TINGLING, AND NAUSEA. INR AT THE HOSPITAL WAS 7.0INR. PT WAS ADMITTED TO THE HOSPITAL OVERNIGHT FOR OBSERVATION AND TO RUN ADD'L TESTS. AT THE TIME OF THIS REPORT, CUSTOMER STATED SHE FEELS BETTER NOW. PT'S THERAPEUTIC RANGE WAS NOT PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
93039 PROTIME 3 CUVETTE ASSAY GJS INTERNATIONAL TECHNIDYNE CORPORATION B2K3H033

Patients

Seq Age Sex Outcome Treatment
1 Hospitalization| R